CY1118975T1 - Παραγωγο μεταστινης και χρηση αυτου - Google Patents

Παραγωγο μεταστινης και χρηση αυτου

Info

Publication number
CY1118975T1
CY1118975T1 CY20171100265T CY171100265T CY1118975T1 CY 1118975 T1 CY1118975 T1 CY 1118975T1 CY 20171100265 T CY20171100265 T CY 20171100265T CY 171100265 T CY171100265 T CY 171100265T CY 1118975 T1 CY1118975 T1 CY 1118975T1
Authority
CY
Cyprus
Prior art keywords
metastatin
cancer
derivative
inhibitory effect
secretion
Prior art date
Application number
CY20171100265T
Other languages
English (en)
Inventor
Taiji Asami
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1118975T1 publication Critical patent/CY1118975T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αποκαλύπτεται ένα σταθερό παράγωγο μεταστίνης που έχει εξαιρετικές βιολογικές δραστικότητες (π.χ., ανασταλτική δραστικότητα καρκινικής μετάστασης, ανασταλτική δραστικότητα πολλαπλασιασμού του καρκίνου, δραστικότητα προώθησης έκκρισης γοναδοτροπίνης, δραστικότητα προώθησης έκκρισης ορμονών του φύλου). Ένα παράγωγο μεταστίνης που παράγεται με υποκατάσταση ενός συστατικού αμινοξέος σε μεταστίνη μπορεί να βελτιωθεί σε σταθερότητα στο αίμα και μπορεί να έχει μια εξαιρετική ανασταλτική δραστικότητα καρκινικής μετάστασης, μια εξαιρετική ανασταλτική δραστικότητα πολλαπλασιασμού του καρκίνου, μια εξαιρετική ανασταλτική δραστικότητα έκκρισης γοναδοτροπίνης, μια εξαιρετική ανασταλτική δραστικότητα έκκρισης ορμονών του φύλου και τα παρόμοια με την πρόσδεση του παραγώγου μεταστίνης σε πολυαιθυλενογλυκόλη.
CY20171100265T 2008-07-30 2017-02-28 Παραγωγο μεταστινης και χρηση αυτου CY1118975T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008196598 2008-07-30
PCT/JP2009/063533 WO2010013762A1 (ja) 2008-07-30 2009-07-29 メタスチン誘導体およびその用途

Publications (1)

Publication Number Publication Date
CY1118975T1 true CY1118975T1 (el) 2018-01-10

Family

ID=41610461

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100265T CY1118975T1 (el) 2008-07-30 2017-02-28 Παραγωγο μεταστινης και χρηση αυτου

Country Status (13)

Country Link
US (1) US20110212890A1 (el)
EP (2) EP2314609B1 (el)
JP (1) JP5698977B2 (el)
CY (1) CY1118975T1 (el)
DK (1) DK2314609T3 (el)
ES (1) ES2617657T3 (el)
HR (1) HRP20170319T1 (el)
HU (1) HUE030900T2 (el)
LT (1) LT2314609T (el)
PL (1) PL2314609T3 (el)
PT (1) PT2314609T (el)
SI (1) SI2314609T1 (el)
WO (1) WO2010013762A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275433B1 (en) * 2008-04-30 2017-06-07 Kyoto University Metastin derivative and use thereof
JP5455661B2 (ja) 2009-01-29 2014-03-26 ギガフォトン株式会社 極端紫外光源装置
EP2755690B1 (en) * 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
IL265696B1 (en) 2016-09-30 2024-04-01 Sumitomo Pharma Switzerland Gmbh -(n-acetyl-d-tyrosyl-trans-4-hydroxy-l-propyl-l-asparaginyl-l-threonyl-l-phenylalenyl) hydrazinocarbonyl-l-leucyl-nω-methyl-l-arginyl-l-tryptophanamide for use in assisted reproductive technology.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
WO2001044469A1 (fr) * 1999-12-17 2001-06-21 Takeda Chemical Industries, Ltd. PROCEDE DE PRODUCTION DE PEPTIDE KiSS-1
EP1273658A4 (en) 2000-03-30 2004-08-11 Takeda Chemical Industries Ltd NEW PROTEIN, THEIR DNA AND METHOD FOR THE PRODUCTION THEREOF
WO2002085399A1 (en) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
EP1428835B1 (en) * 2001-09-19 2007-04-18 Takeda Pharmaceutical Company Limited Antibody against metastin and use of the same in the diagnosis of pregnancy
EP1466976A4 (en) * 2002-01-11 2005-11-09 Takeda Pharmaceutical PROCESS FOR PREPARING KISS-1 PEPTIDES
JPWO2004035089A1 (ja) * 2002-10-09 2006-02-09 協和醗酵工業株式会社 ホルモン依存性癌の治療剤
WO2004063221A1 (ja) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
JP4804714B2 (ja) * 2002-12-26 2011-11-02 武田薬品工業株式会社 メタスチン誘導体およびその用途
US6800611B2 (en) 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
WO2004080479A1 (ja) * 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 性腺機能改善剤
CA2562676A1 (en) * 2004-04-23 2005-12-15 Applied Research Systems Ars Holding N.V. Use of gpcr54 ligands for the treatment of infertility
NZ552029A (en) * 2004-06-25 2009-01-31 Takeda Pharmaceutical Metastin derivatives and use thereof
WO2007084211A2 (en) * 2005-11-11 2007-07-26 The General Hospital Corporation Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP2009530379A (ja) * 2006-03-20 2009-08-27 メルク エンド カムパニー インコーポレーテッド ニューロメジンｕ受容体アゴニスト及びその使用
WO2007109857A1 (en) * 2006-03-28 2007-10-04 Biopharmica Ltd Agent for the treatment of hormone-dependent disorders and uses thereof
WO2007125619A1 (ja) 2006-04-26 2007-11-08 Kyoto University Ｇｐｒ５４アゴニスト活性を有する新規化合物
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
JP4906476B2 (ja) 2006-11-06 2012-03-28 株式会社ブリヂストン タイヤ加硫モールドの洗浄方法
JP2009058102A (ja) 2007-09-03 2009-03-19 Akebono Brake Ind Co Ltd パッドクリップ及び多板ディスクブレーキ
WO2009044918A1 (ja) * 2007-10-05 2009-04-09 Takeda Pharmaceutical Company Limited ニューロメジンｕ誘導体

Also Published As

Publication number Publication date
SI2314609T1 (sl) 2017-05-31
EP2314609A4 (en) 2013-01-16
ES2617657T3 (es) 2017-06-19
US20110212890A1 (en) 2011-09-01
JP5698977B2 (ja) 2015-04-08
PL2314609T3 (pl) 2017-07-31
HRP20170319T1 (hr) 2017-05-05
EP2314609B1 (en) 2016-11-30
JPWO2010013762A1 (ja) 2012-01-12
LT2314609T (lt) 2017-04-10
DK2314609T3 (en) 2017-03-13
EP3210998A1 (en) 2017-08-30
HUE030900T2 (en) 2017-06-28
WO2010013762A1 (ja) 2010-02-04
PT2314609T (pt) 2017-03-06
EP2314609A1 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
CY1118975T1 (el) Παραγωγο μεταστινης και χρηση αυτου
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1122886T1 (el) Αναστολεις βρωμοεπικρατειων
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
ME00786B (me) DERIVATI METASTINA l NJIHOVA UPOTREBA
CY1116970T1 (el) Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης
CR10019A (es) Derivados de mestastina y sus usos
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
ECSP14033037A (es) Síntesis de compuestos heterocíclicos
CY1113819T1 (el) Σκευασματα για τη θεραπευτικη αντιμετωπιση του καρκινου
CL2011001536A1 (es) Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer.
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2008003910A1 (es) Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida.
BRPI1009413A2 (pt) emulsões e adesivos contendo proteína e produção e uso dos mesmos
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CO6511228A2 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
BR112012004391A2 (pt) adesivos de soja/ureia desnaturados com ácido estável e métodos para sua fabricação.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
ECSP11010814A (es) Derivados de ciclohexil-amida y su uso como antagonistas de los receptores de crf-1